Epigenetic therapy in breast cancer

Current Breast Cancer Reports

Volumn 3, Issue 1, 2011, Pages 34-43

  Lustberg, Maryam B ^a   Ramaswamy, Bhuvaneswari ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Demethylating agents; Epigenetic targets; Histone deacetylase inhibitors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BENZAMIDE; BROCCOLI SPROUT EXTRACT; CAPECITABINE; CYCLOPHOSPHAMIDE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; DOXORUBICIN; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE; HYDRALAZINE; LAPATINIB; PACLITAXEL; PANOBINOSTAT; PLANT EXTRACT; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE MAGNESIUM; VALPROIC ACID; VORINOSTAT;

ADVANCED CANCER; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOGENESIS; CANCER THERAPY; CHEMOPROPHYLAXIS; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DNA METHYLATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EPIGENETICS; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION REGULATION; HISTONE MODIFICATION; HUMAN; INTRADUCTAL CARCINOMA; LIVER METASTASIS; LUNG EMBOLISM; LYMPHOCYTOPENIA; LYMPHOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; PROGNOSIS; PROTEIN PROCESSING; SOLID TUMOR; TUMOR MICROENVIRONMENT;

EID: 79951813340     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-010-0034-0     Document Type: Article

References (55)

1. A Bird 2007 Perceptions of epigenetics Nature 447 7143 396 398 1:CAS:528:DC%2BD2sXlsFOgsrk%3D 10.1038/nature05913 17522671 (Pubitemid 46816744)
2. N Maass M Biallek F Rosel C Schem N Ohike M Zhang W Jonat K Nagasaki 2002 Hypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancer Biochem Biophys Res Commun 297 1 125 128 1:CAS:528:DC%2BD38Xms1Gntb8%3D 10.1016/S0006-291X(02)02136-8 12220518
3. VZQ Stearns NE Davison 2007 Epigenetic Regulation as a New Target for Breast Cancer Therapy Cancer Investigation 25 659 665 1:CAS:528: DC%2BD2sXhtl2isrvE 10.1080/07357900701719234 18058459 (Pubitemid 350223167)
4. PPM Yan D Laux A Asare C Caldwell T Huang 2000 CpG Island Arrays: An application toward Deciphering epigenetic signatures of breast cancer Clinical Cancer Research 6 1432 1438 1:CAS:528:DC%2BD3cXjtVOqtL0%3D 10778974 (Pubitemid 30226231)
5. Portela A, Esteller M: Epigenetic modifications and human disease. Nat Biotechnol, 28(10):1057-1068.
6. M Esteller 2007 Cancer epigenomics: DNA methylomes and histone-modification maps Nat Rev Genet 8 4 286 298 1:CAS:528: DC%2BD2sXivVGktbk%3D 10.1038/nrg2005 17339880 (Pubitemid 46439286)
7. L Giacinti PP Claudio M Lopez A Giordano 2006 Epigenetic information and estrogen receptor alpha expression in breast cancer Oncologist 11 1 1 8 1:CAS:528:DC%2BD28XhtFKlsbzF 10.1634/theoncologist.11-1-1 16401708 (Pubitemid 43152681)
8. Lopez-Serra L, Ballestar E, Ropero S, Setien F, Billard LM, Fraga MF, Lopez-Nieva P, Alaminos M, Guerrero D, Dante R et al.: Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins. Oncogene 2008.
9. M Esteller 2008 Epigenetics in Cancer The New England Journal of Medicine 358 1148 1159 1:CAS:528:DC%2BD1cXjt1ahs7Y%3D 10.1056/NEJMra072067 18337604 (Pubitemid 351398489)
10. SE Elsheikh AR Green EA Rakha DG Powe RA Ahmed HM Collins D Soria JM Garibaldi CE Paish AA Ammar, et al. 2009 Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome Cancer Res 69 9 3802 3809 1:CAS:528:DC%2BD1MXltFOks7g%3D 10.1158/0008-5472.CAN- 08-3907 19366799
11. MF Fraga E Ballestar A Villar-Garea M Boix-Chornet J Espada G Schotta T Bonaldi C Haydon S Ropero K Petrie, et al. 2005 Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer Nat Genet 37 4 391 400 1:CAS:528:DC%2BD2MXislCmurg%3D 10.1038/ng1531 15765097
12. Y Wei W Xia Z Zhang J Liu H Wang NV Adsay C Albarracin D Yu JL Abbruzzese GB Mills, et al. 2008 Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers Mol Carcinog 47 9 701 706 1:CAS:528:DC%2BD1cXhtVCrsbnM 10.1002/mc.20413 18176935
13. KN Harikrishnan MZ Chow EK Baker S Pal S Bassal D Brasacchio L Wang JM Craig PL Jones S Sif, et al. 2005 Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing Nat Genet 37 3 254 264 1:CAS:528:DC%2BD2MXhsFOqu7o%3D 10.1038/ng1516 15696166 (Pubitemid 41716252)
14. U Lehmann B Hasemeier M Christgen M Muller D Romermann F Langer H Kreipe 2008 Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer J Pathol 214 1 17 24 1:CAS:528:DC%2BD1cXhtlynu7g%3D 10.1002/path.2251 17948228 This is a study of epigenetic regulation of miRs in breast cancer
15. MA Matzke MF Mette T Kanno AJ Matzke 2003 Does the intrinsic instability of aneuploid genomes have a causal role in cancer? Trends Genet 19 5 253 256 1:CAS:528:DC%2BD3sXjtFeqtrc%3D 10.1016/S0168-9525(03)00057-X 12711216 (Pubitemid 36507006)
16. K Polyak I Haviv IG Campbell 2009 Co-evolution of tumor cells and their microenvironment Trends Genet 25 1 30 38 1:CAS:528:DC%2BD1MXosVSktA%3D%3D 10.1016/j.tig.2008.10.012 19054589
17. TJ Peterson S Karmakar MC Pace T Gao CL Smith 2007 The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity Mol Cell Biol 27 17 5933 5948 1:CAS:528:DC%2BD2sXpvFGgsb0%3D 10.1128/MCB.00237-07 17591692 (Pubitemid 47333769)
18. X Yang DL Phillps AT Fergusson, et al. 2001 Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells Cancer Res 16 7025 7029 (Pubitemid 32946489)
19. Q Zhou P Atadja NE Davidson 2007 Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation Cancer Biol Ther 6 1 64 69 1:CAS:528:DC%2BD2sXhtVeqsb7P 10.4161/cbt.6.1.3549 17172825 (Pubitemid 46294178)
20. K Subramanian D Jia P Kapoor-Vazirani DR Powell RE Collins D Sharma J Peng X Cheng PM Vertino 2008 Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase Mol Cell 30 3 336 347 1:CAS:528:DC%2BD1cXmtFaktLs%3D 10.1016/j.molcel.2008.03.022 18471979 (Pubitemid 351615317)
21. YW Leu PS Yan M Fan VX Jin JC Liu EM Curran WV Welshons SH Wei RV Davuluri C Plass, et al. 2004 Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer Cancer Res 64 22 8184 8192 1:CAS:528:DC%2BD2cXpvVGlur4%3D 10.1158/0008-5472.CAN-04-2045 15548683 (Pubitemid 39491754)
22. RG Lapidus AT Ferguson YL Ottaviano FF Parl HS Smith SA Weitzman SB Baylin JP Issa NE Davidson 1996 Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors Clin Cancer Res 2 5 805 810 1:CAS:528:DyaK28XjsVamtLg%3D 9816234
23. Fleury L, Gerus M, Lavigne AC, Richard-Foy H, Bystricky K: Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells. Oncogene 2008.
24. E Badia MJ Duchesne A Semlali M Fuentes C Giamarchi H Richard-Foy JC Nicolas M Pons 2000 Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling Cancer Res 60 15 4130 4138 1:CAS:528: DC%2BD3cXlvFOkt7w%3D 10945620 (Pubitemid 30636595)
25. K Terada E Okochi-Takada S Akashi-Tanaka K Miyamoto K Taniyama H Tsuda K Asada M Kaminishi T Ushijima 2009 Association between frequent CpG island methylation and HER2 amplification in human breast cancers Carcinogenesis 30 3 466 471 1:CAS:528:DC%2BD1MXivFSiur4%3D 10.1093/carcin/bgp021 19168584
26. H Fiegl S Millinger G Goebel E Muller-Holzner C Marth PW Laird M Widschwendter 2006 Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer Cancer Res 66 1 29 33 1:CAS:528:DC%2BD28XhsFWgug%3D%3D 10.1158/0008-5472.CAN-05-2508 16397211 (Pubitemid 43166004)
27. PPM Bali R Swaby W Fiskus H Yamaguchi M Balasis K Rocha H Wang V Richon K Bhalla 2005 Activity of Suberoylanilide Hydroxamic acid against human breast cancer cells with amplificatoin of Her 2 Clinical Cancer Research 11 17 6382 6389 1:CAS:528:DC%2BD2MXpslansbk%3D 10.1158/1078-0432.CCR-05-0344 16144943 (Pubitemid 41262970)
28. LBP Fuino S Wittman, et al. 2003 Histone deacetylse inhibitor LAQ824 down regulated Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B Mol Cancer Ther 2 971 984 1:CAS:528:DC%2BD3sXosVCqt7g%3D
29. XFA Yang SJ Nass 2000 Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone decetylase inhibition Cancer Res 60 6890 6894 1:CAS:528:DC%2BD3MXjsVKqug%3D%3D 11156387 (Pubitemid 32059160)
30. MF Robert S Morin N Beaulieu, et al. 2003 DNMT1 is requiered to maintain CpG methylation and aberrant gene silencing in human cancer cells Nat Genet 33 61 65 1:CAS:528:DC%2BD38XpvVeqsL4%3D 10.1038/ng1068 12496760 (Pubitemid 36068683)
31. JC Cheng CB Yoo DJ Weisenberger J Chuang C Wozniak G Liang VE Marquez S Greer TF Orntoft T Thykjaer, et al. 2004 Preferential response of cancer cells to zebularine Cancer Cell 6 2 151 158 1:CAS:528:DC%2BD2cXns1arsro%3D 10.1016/j.ccr.2004.06.023 15324698 (Pubitemid 39485687)
32. A Stathis S Hottie H Hirte, et al. 2009 Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL) J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695 (suppl; abstr 3528). This is a phase I study of DNMT inhibitor in combination with HDACi in solid tumors
33. C Arce C Perez-Plasencia A Gonzalez-Fierro E de la Cruz-Hernandez A Revilla-Vazquez A Chavez-Blanco C Trejo-Becerril E Perez-Cardenas L Taja-Chayeb E Bargallo, et al. 2006 A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer PLoS ONE [Electronic Resource] 1 e98 10.1371/journal.pone.0000098
34. M Candelaria D Gallardo-Rincon C Arce L Cetina JL Aguilar-Ponce O Arrieta A Gonzalez-Fierro A Chavez-Blanco E de la Cruz-Hernandez MF Camargo, et al. 2007 A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Annals of Oncology 18 9 1529 1538 1:STN:280:DC%2BD2srhtFaqug%3D%3D 10.1093/annonc/ mdm204 17761710 (Pubitemid 47365487)
35. JS Isaacs W Xu L Neckers 2003 Heat shock protein 90 as a molecular target for cancer therapeutics Cancer Cell 3 3 213 217 1:CAS:528:DC%2BD3sXislOrtb8%3D 10.1016/S1535-6108(03)00029-1 12676580 (Pubitemid 37443877)
36. P Bali M Pranpat R Swaby W Fiskus H Yamaguchi M Balasis K Rocha HG Wang V Richon K Bhalla 2005 Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2 Clinical Cancer Research 11 17 6382 6389 1:CAS:528:DC%2BD2MXpslansbk%3D 10.1158/1078-0432.CCR-05-0344 16144943 (Pubitemid 41262970)
37. S Thomas PN Munster 2009 Histone deacetylase inhibitor induced modulation of anti-estrogen therapy Cancer Lett 280 2 184 191 1:CAS:528: DC%2BD1MXmsF2jt7s%3D 10.1016/j.canlet.2008.12.026 19185986
38. PN Munster T Troso-Sandoval N Rosen R Rifkind PA Marks VM Richon 2001 The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells Cancer Res 61 23 8492 8497 1:CAS:528:DC%2BD3MXptFCkur8%3D 11731433 (Pubitemid 33131130)
39. W Fiskus Y Ren A Mohapatra P Bali A Mandawat R Rao B Herger Y Yang P Atadja J Wu, et al. 2007 Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90 Clin Cancer Res 13 16 4882 4890 1:CAS:528:DC%2BD2sXptVGmtL0%3D 10.1158/1078-0432.CCR-06-3093 17699868 (Pubitemid 47294796)
40. E Bicaku DC Marchion ML Schmitt PN Munster 2008 Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling Cancer Res 68 5 1513 1519 1:CAS:528:DC%2BD1cXislagu7Y%3D 10.1158/0008-5472.CAN-07-2822 18316616 (Pubitemid 351346860)
41. DC Marchion E Bicaku AI Daud V Richon DM Sullivan PN Munster 2004 Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid J Cell Biochem 92 2 223 237 1:CAS:528:DC%2BD2cXjvVaqs7c%3D 10.1002/jcb.20045 15108350
42. WK Kelly VM Richon O O'Connor, et al. 2003 Phase I clinical trial of histone deacetylase inhibitor suberoylanilide hydroxamic acid administered intravenously Clin Cancer Res 9 3578 3588 1:CAS:528:DC%2BD3sXosVOlurg%3D 14506144 (Pubitemid 37169221)
43. WK Kelly OA O'Connor LM Krug, et al. 2005 Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid in patients with advanced cancer J Clin Oncol 23 3923 3931 1:CAS:528:DC%2BD2MXmtVahtLw%3D 10.1200/JCO.2005.14.167 15897550 (Pubitemid 46218695)
44. TH Luu RJ Morgan L Leong, et al. 2008 A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium Study Clinical Cancer Research 14 7138 7142 1:CAS:528:DC%2BD1cXhtlensL7I 10.1158/1078-0432.CCR-08-0122 18981013
45. PN Munster M Lacevic S Thomas C Christian R Ismail-Khan M Melisko HE Rugo SE Minton 2009 Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy J Clin Oncol 27 15S May 20 Supplement 1075 This is a proof-of-principle study showing the effects of vorinostat in reverting tamoxifen resistance
46. AM Wardley RS J McCaffrey J Crown Z Malik D Rea PJ Barrett-Lee GT Lee 2010 Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy J Clin Oncol 28 15s suppl; abstr 1052
47. • Ramaswamy B BK, Cohen B, et al.: Phase II trial of the histone deacetylase inhibitor (HDACi) vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer (MBC): New York Cancer Consortium Trial 7703. AACR 100th Annual Meeting April 18-22 2009, 09-AB4116-AACR Denver, CO. This is an important study demonstrating the benefits of combining chemotherapy and vorinostat in breast cancer.
48. P Munster D Marchion E Bicaku M Schmitt JH Lee R DeConti G Simon M Fishman S Minton C Garrett, et al. 2007 Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study J Clin Oncol 25 15 1979 1985 1:CAS:528:DC%2BD2sXmvVWmsrg%3D 10.1200/JCO.2006.08.6165 17513804 (Pubitemid 46972780)
49. R. Swaby MW, J. Sparano, K. Bhalla, N. Meropol, C. Falkson, C. Pellegrino, P. Klein, L. Goldstein and G. Sledge, Jr: A Phase II Study of the Histone Deacetylase Inhibitor, Vorinostat, in Combination with Trastuzumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent HER-2 Amplified Breast Cancer Resistant to Transtuzumab-Containing Therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group. Cancer Res 2009, 69(24 Suppl):Abstract nr 5084.
50. P Conte M Campone P Pronzato D Amadori R Frank F Schuetz D Rea A Wardley C Britten A Elias 2009 Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results Journal of Clinical Oncology 27 15S May 20 Supplement 1081 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
51. NW Peacock SF Jones DA Yardley JC Bendell JR Infante PB Murphy HA Burris III 2010 A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib J Clin Oncol 28 15s suppl; abstr 1115
52. Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D et al.: DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat 2007.
53. H Fiegl A Jones C Hauser-Kronberger G Hutarew R Reitsamer RL Jones M Dowsett E Mueller-Holzner G Windbichler G Daxenbichler, et al. 2008 Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer Clin Cancer Res 14 11 3494 3502 1:CAS:528:DC%2BD1cXmslygtro%3D 10.1158/1078-0432.CCR-07-4557 18519782
54. M Widschwendter S Apostolidou E Raum D Rothenbacher H Fiegl U Menon C Stegmaier IJ Jacobs H Brenner 2008 Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study PLoS ONE 3 7 e2656 10.1371/journal.pone.0002656 18628976 This article presents the first blood-based study of methylation profiles in breast cancer
55. R Radpour C Kohler MM Haghighi AX Fan W Holzgreve XY Zhong 2009 Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array Oncogene 28 33 2969 2978 1:CAS:528:DC%2BD1MXntVWit74%3D 10.1038/onc.2009.149 19503099 This article reviews a new method for genome-wide methylation studies